Graphic from Time

Pfizer’s Twitter feed seems to be benefiting from the same ingredient that powers its blockbuster erectile drug.

After only six days @pfizer_news had jumped to 631 followers by 8 o’clock this morning.

Kudos to communications SVP Sally Sussman and global media VP Ray Kerins for prevailing in a heavily regulated industry whose litigation-wary greybeards are notoriously conservative when it comes to social media.

Pharma lawyers have argued that any communications through channels feeding directly to patients — without the traditional bureaucratic review of copy, photos, video and other content — could go south quickly.

“What if” scenarios abound.  In a litigious world where the prescribing information required by regulators is often the size of an encylopedia, it’s easy to see a plaintiff complaining that he or she notified a drugmaker about an adverse reaction via Twitter but got no reply only to suffer….

For those and many other reasons, pharma has arrived later to the Twitter party than many other consumer-facing brands.  Those brave enough to tweet about remedies, clinical trials and medical conferences have taken markedly different approaches.

The most conversational pharmatweep this far is Johnson & Johnson’s Marc Monseau, who is followed by 1,745 and follows 1,096.  He has updated 316 times since launching the @JNJComm feed to supplement the New Jersey firm’s two-year-old “JNJ BTW” blog.

Novartis, based in Switzerland, has published 86 updates on its @novartis Twitter feed since November.  Unlike Monseau, there’s no named personality behind the tweets,  which are mainly 140-character teasers of releases on the Novartis media web site and some occasional industry news.  The lack of interaction is stark — with the company following only 10 on Twitter despite attracting an audience of 2,328.

Germany’s Boehringer was lauded by Jim Edwards on the life sciences news site BioValley Basel for allowing its Twitter personality — 2,178 followers and following 1,657 — to “engage in some harmless banter” rather than toeing the corporate line.

Merck seems to be using the Twitter community only as a recruiting tool, but I question how many Twitter users want to work for a company that’s afraid to engage in a more meaningful way.

In New York, Pfizer’s new Twitter staffers were quick to reply today when I sent a direct message to ask why there were a separate @pfizer (”it’s not Pfizer and not official”) and @pfizer_news Twitter pages.  That kind of willingness to snap quick replies to customers, media and others can only help build trust and goodwill with everyone except the legal department.

An unfortunate truth is that many kids’ breakfast food choices are based on the appeal of cartoon rabbits, toucans and elephants touting sugary cereals.

But we grow out of that kind of consumerism, right?

Similar marketing seems to be working well on grown men and women. Advertising the solutions to solve some of the human body’s most repulsive maladies now is done with the help of comical animated characters.

Digger, the sharp-clawed enemy of toe nails, spread faster than athlete’s foot when introduced by Novartis as the cartoon personification of its Lamisil brand. I am sure Digger’s face is being used as an avatar by more than a few teens.

Reckitt Benckiser Inc.’s over-the-counter line of expectorants, Mucinex, has a whole family of green phlegm characters to illustrate how fast a booger can move when the right medicine arrives on the scene.

Outside of pharma, the Düsseldorf, Germany, office of BBDO recently introduced a tiny blue cartoon being, in the form of a single calorie, for PepsiCo’s Pepsi Max diet cola. Print ads were posted on the European ad-gallery site adgoodness.com, prompting plenty of controversy over the fact that the calorie commits suicide because it’s lonely. AdAge has since written on the campaign and subsequent outcry from those arguing the issue of suicide is sacrosanct.

I recall one B2B company in the investor relations industry that successfully linked its brand to a cartoonist’s creation. an online database of fund managers and other financial industry contacts, used the image of a baby, dressed in a top hat, throwing around cash. At one memorable conference for the National Investor Relations Institute, Big Dough startled more than a few of normally staid IR officers when it employed a Disneyesque costumed character – a seven-foot-tall baby – to walk around the exhibition hall. Whether the non-traditional marketing approached helped I don’t know, but Big Dough captured plenty of market share among corporate users before being rebranded as part of a larger suite of Ipreo’s services.

I’m guessing we don’t see more B2B businesses tied to fictional characters or cartoon imagery because so much of an organization’s success rides on the credibility and message of the CEO. Marketing officers at B2B firms spend their time making sure the CEO succeeds as chief storyteller and cheerleader for the brand and its heritage.

But given the global crisis of confidence regarding the integrity of executives leading businesses of all sizes, I can’t actually see the downside of making a B2B firm’s CEO sharing the limelight with someone a bit more believable and, yes, fun.  The “Why is Dora Crying?” ad in major newspapers last week was a damn effective way for Viacom to pressure Time Warner to cut a better deal to keep Nick Jr. on its cable systems.

Granted, most specialty chemical companies, makers of superconductors and developers of enterprise accounting software do not have the corporate culture or desire to support borrowing from the consumer marketing toolbox.

But many of the customers and employees of those same conservative organizations privately cheer for the underdog breakout firms who occasionally pop onto the scene and take our breath away because they refuse to conform to conventional wisdom.

Assuming we ever get the steel industry going again in the United States, I’d love to see a fire-breathing dragon conduct the quarterly results conference call.